In Lilly's three-year SURMOUNT-1 trial, 1,032 pre-diabetic subjects were given tirzepatide or a placebo, showing a remarkable 94% reduced risk of diabetes.
The study's findings suggest that the drug not only significantly lowers the risk of developing diabetes but also maintains an 88% reduced risk even after discontinuation.
While exercise and diet remain essential for reducing diabetes risk, these weight loss injectables present a compelling alternative with lasting protective effects.
The SURMOUNT-1 trial is notable as the longest study to date on this class of drugs, demonstrating crucial insights into their effectiveness in a real-world setting.
Collection
[
|
...
]